# US 2013/0296642 A1 · Biomarkers and method for predicting occurence of ventral hernias

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296642 A1
- Document ID: US20130296642A1
- Status: Published application
- Kind: A1
- Application number: 13/827,472
- Filed: 2013-03-14
- Published: 2013-11-07
- Earliest claimed: 2012-03-24
- Assignees: Curators of the University
- Applicants: The Curators of the University of
- Inventors: Ulus Atasoy; Sharon L. Bachman; Robert Calaluce; Wade Davis; Bruce J. Ramshaw
- Web page: https://patentgrep.com/patent/US20130296642A1

## CPC

- A61F 2/0063: {Implantable repair or support meshes, e.g. hernia meshes}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Kits, methods of treating, and methods of diagnosing a risk level for an incisional hernia in a subject undergoing abdominal surgery are disclosed. They are designed to determine risk factors for incisional hernia formation based on a subject's unique gene expression profiles.

## Claims

### Claim 1

A method of treating an abdominal surgical incision in a subject in need thereof comprising the steps of:
a. measuring the level of expression of a gene or combination of genes selected from the group consisting of COL1A2, COL3A1, GREM1, and IL10 in a tissue sample obtained from the subject;
b. comparing the level of expression of the gene or combination of genes in the tissue sample to that in a control sample;
c. determining a risk level for an incisional hernia in the subject following surgery, wherein the subject has a high risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a greater than 1.5 fold change compared to the level of expression of the gene or combination of genes in the control sample, and a normal risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a 1.5 fold change or less compared to the level of expression of the gene or combination of genes in the control sample; and
d. treating the subject based upon the subject's risk level for an incisional hernia as determined in step c.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tissue sample is obtained from the subject's skin, blood, or fascia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the gene is GREM1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has a high risk for an incisional hernia if the level of expression of GREM1 in the subject's tissue sample is lower than the level of expression of GREM1 in the control sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has a high risk for an incisional hernia if the level of expression of COL1A2, COL3A1, or IL10, or combinations thereof, in the subject's tissue sample is higher than that in the control sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the level of gene expression in a. or b. is measured by microarray, PCR array, or immunohistochemistry.

### Claim 7 (depends on 1)

The method of claim 1, wherein the level of gene expression in a. and b. is measured via the quantity of nucleic acid transcripts produced by the gene or combination of genes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene expression is measured via the quantity of protein expressed from the gene or combination of genes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject determined to have a high risk for an incisional hernia is treated with placement of surgical mesh in the abdominal incision.

### Claim 10 (depends on 9)

The method of claim 9, wherein the surgical mesh is affixed to abdominal tissue bridging the abdominal incision.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject determined to have a high risk for an incisional hernia is treated with laparoscopic surgery.

### Claim 12

A method of diagnosing a risk level for an incisional hernia in a subject following abdominal surgery, comprising the steps of:
a. measuring the level of expression of a gene or combination of genes selected from the group consisting of COL1A2, COL3A1, GREM1, and IL10 in a tissue sample obtained from the subject;
b. comparing the level of expression of the gene or combination of genes in the tissue sample to that in a control sample;
c. determining a risk level for an incisional hernia in the subject following surgery,
wherein the subject has a high risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a greater than 1.5 fold change compared to the level of expression of the gene or combination of genes in the control sample, and a normal risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a 1.5 fold change or less compared to the level of expression of the gene or combination of genes in the control sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the tissue sample is obtained from the subject's skin, blood, or fascia.

### Claim 14 (depends on 12)

The method of claim 12, wherein the gene is GREM1.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject has a high risk for an incisional hernia if the level of expression of GREM1 in the subject's tissue sample is lower than the level of expression of GREM1 in the control sample.

### Claim 16 (depends on 12)

The method of claim 12, wherein the subject has a high risk for an incisional hernia if the level of expression of COL1A2, COL3A1, or IL10, or combinations thereof, in the subject's tissue sample is higher than that in the control sample.

### Claim 17 (depends on 12)

The method of claim 12, wherein the level of gene expression in a. or b. is measured by microarray, PCR array, or immunohistochemistry.

### Claim 18 (depends on 12)

The method of claim 12, wherein the level of gene expression in a. and b. is measured via the quantity of nucleic acid transcripts produced by the gene or combination of genes.

### Claim 19 (depends on 12)

The method of claim 12, wherein the gene expression is measured via the quantity of protein expressed from the gene or combination of genes.

### Claim 20

A product comprising isolated biomarkers bound to a biochip array, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, IL10, and combinations thereof.

### Claim 21 (depends on 20)

The product of claim 20, wherein the biomarker is GREM1.

### Claim 22

A product comprising purified biomarkers bound to a microarray comprising addressable locations using a biospecific capture reagent, wherein the biomarkers are a gene or combination of genes selected from the group consisting of COL1A2, COL3A1, GREM1, and IL10.

### Claim 23 (depends on 22)

A product of claim 22, wherein the biomarker is GREM1.

### Claim 24

A kit for diagnosing a risk level for an incisional hernia in a subject following abdominal surgery, comprising:
a. purified biomarkers bound to a microarray comprising addressable locations using an adsorbent or capture reagent, wherein the purified biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, or combinations thereof, and
b. written instructions for diagnosing a risk level for an incisional hernia in a subject following abdominal surgery, comprising the steps of:
i. measuring the level of expression of a gene or combination of genes selected from the group consisting of COL1A2, COL3A1, GREM1, and IL10 in a tissue sample obtained from the subject;
ii. comparing the level of expression of the gene or combination of genes in the tissue sample to that in a control sample;
iii. determining a risk level for an incisional hernia in the subject following surgery,
wherein the subject has a high risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a greater than 1.5 fold change compared to the level of expression of the gene or combination of genes in the control sample, and a normal risk for an incisional hernia if the level of expression of the gene or combination of genes in the subject's tissue sample displays a 1.5 fold change or less compared to the level of expression of the gene or combination of genes in the control sample.

### Claim 25 (depends on 24)

The kit of claim 24, wherein the biomarker is GREM1.

### Claim 26

A biochip array comprising isolated biomarkers, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 27 (depends on 26)

The biochip array of claim 26, wherein the biomarker is GREM1.

### Claim 28

A biochip array having a plurality of addressable locations, each comprising at least one isolated biomarker, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 29 (depends on 28)

The biochip array of claim 28, wherein the biomarker is GREM1.

### Claim 30 (depends on 28)

The biochip array of claim 28, having at least two addressable locations, each comprising at least one isolated biomarker, wherein the two or more biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 31 (depends on 28)

The biochip array of claim 28, having at least three addressable locations, each comprising at least one isolated biomarker, wherein the three or more biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 32 (depends on 28)

The biochip array of claim 28, having at least four addressable locations, each comprising at least one isolated biomarker, wherein the four biomarkers are COL1A2, COL3A1, GREM1, and IL10.

### Claim 33

A product comprising at least one isolated biomarker bound to a bead by a biospecific capture reagent, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 34 (depends on 33)

The product of claim 33, wherein one biomarker is bound to the bead.

### Claim 35 (depends on 34)

The product of claim 34, wherein the biomarker is GREM1.

### Claim 36 (depends on 35)

The product of claim 35, wherein the biospecific capture reagent is an antibody.

### Claim 37 (depends on 34)

The product of claim 34, comprising a plurality of beads of at least one bead type, wherein each bead type comprises an isolated biomarker bound to the bead by a biospecific capture reagent, and wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, and IL10.

### Claim 38 (depends on 37)

The product of claim 37, wherein the biospecific capture reagent is an antibody.

### Claim 39 (depends on 37)

The product of claim 37, comprising at least two bead types.

### Claim 40 (depends on 37)

The product of claim 37, comprising at least three bead types.

### Claim 41 (depends on 37)

The product of claim 37, comprising at least four bead types.

### Claim 42 (depends on 30)

The product of claim 30, comprising at least two isolated biomarkers bound to a bead by a biospecific capture reagent, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 43 (depends on 42)

The product of claim 42, wherein the biomarker is GREM1.

### Claim 44 (depends on 42)

The product of claim 42, wherein the biospecific capture reagent is an antibody.

### Claim 45

A biochip comprising one or more isolated biomarkers, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 46 (depends on 45)

The biochip of claim 45, wherein the biomarker is GREM1.

### Claim 47 (depends on 45)

The biochip of claim 45, wherein the isolated biomarkers are present at addressable locations.

### Claim 48 (depends on 47)

The biochip of claim 47, having at least two addressable locations, each comprising a different isolated biomarker, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 49 (depends on 47)

The biochip of claim 47, having at least three addressable locations, each comprising a different isolated biomarker, wherein the biomarkers are selected from the group consisting of COL1A2, COL3A1, GREM1, IL10, and combinations thereof.

### Claim 50 (depends on 47)

The biochip of claim 47, having at least four addressable locations, each comprising a different isolated biomarker, wherein the biomarkers are COL1A2, COL3A1, GREM1, and IL10.
